Market Report Source

Overview

Introduction
Interstitial cystitis (IC) is considered a rare disorder and poor understanding of the underlying causes of the disorder have made diagnosis and management difficult. Moreover, this has impacted on the development of effective drugs for this disorderthere are few available treatments for IC and as a result, significant unmet needs exist.

Scope
Quantitative treatment data from 190 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to second-line treatments for IC
Influences on treatment choice and perception of current drug therapies including pentosan polysulfate sodium and the antimuscarinics
Influences on treatment choice and perception of current drug therapies, unmet needs and future outlook including the R&D drug pipeline

Highlights
Presentation rates for IC are higher than in other OAB disorders due to the patient experience of pain. However, discord in the terminology and diagnostic criteria for IC confound diagnosis; and as result, the diagnosis of IC tends to be one of exclusion, and as such can take many years to be reached, bringing unnecessary suffering to the patient.

IC symptoms have a similar terminology to those of Overactive Bladder, but are fundamentally different. Poor understanding of the disorder and limited treatment options means that many physicians have resorted to using antimuscarinics despite their limited proven efficacy in treating the pain.

Further research into the etiology of IC is the key to finding a truly effective treatment for IC that works. In the meantime, companies wishing to target the IC market should aim to demonstrate the ability of their drug to treat pain in addition to urgency and frequency.

Reasons to Purchase
Forecast product sales by understanding key aspects of IC epidemiology, diagnosis and treatment
Gain a better understanding of the challenges facing current and future players in the IC market
Identify physicians key concerns in IC including unmet needs and the attributes that physicians believe are desirable for future treatments

Table of Contents

TABLE OF CONTENTS
OVERVIEW
This product has been designed for delivery in a slide pack format (PowerPoint).
Please select the slide pack option from the download menu at the side of the page
Introduction
Scope of this report
Research and analysis highlights
Key reasons to read this report
APPENDIX A
Research methodology
Physician Sample breakdown
Urinary Incontinence and Overactive Bladder Insight Study – Physician Questionnaire
Section One Overview of Urinary Incontinence and overactive Bladder
Epidemiology
Presentation
Diagnosis
Referral pattern
Section Two Stress Urinary Incontinence
Diagnosis and treatment of SUI
Non-pharmacological treatment
Pharmacological treatment for SUI
Section Three Overactive Bladder With Urge Symptoms and/or Incontinence
Diagnosis and treatment of UUI
Pharmacological treatment for UUI
Diagnosis and treatment of ‘dry OAB’
Pharmacological treatment for dry OAB
Section Four Mixed Stress/Urge Urinary Incontinence
Diagnosis and treatment of mixed SUI/UUI
Non-pharmacological treatment
Pharmacological treatment for mixed SUI/UUI
Section Five Interstitial Cystitis
Diagnosis and treatment of IC
Pharmacological treatment for IC
Section Six Drug Profiles
Section A: Drug influences on physicians’ choice
Section B: The general treatment of urinary incontinence and overactive bladder
Contributing experts
US
Japan
Europe
APPENDIX B
About Datamonitor
About Datamonitor Healthcare
About the CNS analysis team
Disclaimer